| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Ventas (NYSE:VTR) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 2 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Ventas, revealing an average target of $51.75, a high estimate of $56.00, and a low estimate of $47.00. This upward trend is evident, with the current average reflecting a 6.7% increase from the previous average price target of $48.50.
In examining recent analyst actions, we gain insights into how financial experts perceive Ventas. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joshua Dennerlein | B of A Securities | Raises | Buy | $53.00 | $48.00 |
| Vikram Malhorta | Mizuho | Raises | Buy | $56.00 | $53.00 |
| Connor Siversky | Wells Fargo | Lowers | Overweight | $47.00 | $49.00 |
| Richard Anderson | Wedbush | Raises | Outperform | $51.00 | $44.00 |
To gain a panoramic view of Ventas's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Ventas analyst ratings.
Ventas owns a diversified healthcare portfolio of nearly 1,400 in-place properties spread across the senior housing, medical office, hospital, life science, and skilled nursing/post-acute care. The portfolio includes over 40 properties in Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to the United States. The firm also owns mortgages and other loans, contributing about 3% of net operating income.
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Ventas's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 10.85%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Real Estate sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -6.19%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Ventas's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -0.72%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Ventas's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.28%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Ventas's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.38.
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: VTR
